LM-299

Pfizer has secured global rights (excluding China) to 3SBio's experimental cancer drug SSGJ-707 for $1.25 billion upfront, with potential additional payments of up to $4.8 billion based on developmental milestones.

Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.

Merck has secured exclusive global rights (excluding Greater China) to HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor currently in Phase 2 trials in China.

Ocean Biomedical's breakthrough research demonstrates their immunotherapy candidates can synergize with tyrosine kinase inhibitors like osimertinib to suppress tumor growth in EGFR-mutant lung cancer.

Jefferies has upgraded Instil Bio, citing the promising potential of its investigational cancer drug SYN2510. The upgrade follows significant clinical trial updates and a bullish outlook on the PD-(L)1xVEGF class, with Jefferies estimating a market potential of over $40 billion. Instil Bio's stock saw a substantial increase, reflecting the industry's optimism towards SYN2510's clinical and commercial prospects.